185 related articles for article (PubMed ID: 33968671)
1. Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report.
Ni K; Wang Z; Yu S; Zheng J; Li G
Transl Androl Urol; 2021 Apr; 10(4):1821-1826. PubMed ID: 33968671
[TBL] [Abstract][Full Text] [Related]
2. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.
Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M
Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042
[TBL] [Abstract][Full Text] [Related]
3. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
4. Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.
Xu T; Guo H; Xie J; He Y; Che J; Peng B; Yang B; Yao X
Front Oncol; 2023; 13():1119343. PubMed ID: 37427135
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
Lu Y; Kang J; Luo Z; Song Y; Tian J; Li Z; Wang X; Liu L; Yang Y; Liu X
Front Oncol; 2020; 10():1400. PubMed ID: 32974145
[No Abstract] [Full Text] [Related]
6. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
[TBL] [Abstract][Full Text] [Related]
7. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature.
Gust KM; Resch I; D'Andrea D; Shariat SF
Transl Androl Urol; 2021 Oct; 10(10):4051-4061. PubMed ID: 34804847
[TBL] [Abstract][Full Text] [Related]
8. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation.
Zhang L; Xiong G; Fang D; Li X; Liu J; Ci W; Zhao W; Singla N; He Z; Zhou L
J Exp Clin Cancer Res; 2015 Jan; 34(1):5. PubMed ID: 25613404
[TBL] [Abstract][Full Text] [Related]
9. Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies.
Evmorfopoulos K; Mitrakas L; Karathanasis A; Zachos I; Tzortzis V; Vlachostergios PJ
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509415
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
Seisen T; Peyronnet B; Dominguez-Escrig JL; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Cowan NC; Kaasinen E; Palou J; van Rhijn BW; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
Eur Urol; 2016 Dec; 70(6):1052-1068. PubMed ID: 27477528
[TBL] [Abstract][Full Text] [Related]
11. Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience.
Campi R; Cotte J; Sessa F; Seisen T; Tellini R; Amparore D; Mormile N; Gobert A; Mari A; Porpiglia F; Serni S; Minervini A; Rouprêt M
World J Urol; 2019 Nov; 37(11):2303-2311. PubMed ID: 31062121
[TBL] [Abstract][Full Text] [Related]
12. Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.
Ding X; Zong J; Li X; Bai X; Tan B; Sun W; Wang R; Ding Y
Onco Targets Ther; 2021; 14():2177-2183. PubMed ID: 33790580
[TBL] [Abstract][Full Text] [Related]
13. High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma.
Széles Á; Kovács PT; Csizmarik A; Váradi M; Riesz P; Fazekas T; Váncsa S; Hegyi P; Oláh C; Tschirdewahn S; Darr C; Krafft U; Grünwald V; Hadaschik B; Horváth O; Nyirády P; Szarvas T
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289821
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
15. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
Chen Y; Zhang H; Shi J; Wang T
Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
17. Effects of Adjuvant Chemotherapy on Locally Advanced Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.
Kim DK; Kim JW; Jung HD; Ahn HK; Lee JY; Cho KS
Clin Genitourin Cancer; 2019 Dec; 17(6):e1193-e1202. PubMed ID: 31543442
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review.
Ni K; Yu C; Wang H; Zhu S; Yu S; Li G
Heliyon; 2023 May; 9(5):e15813. PubMed ID: 37206016
[TBL] [Abstract][Full Text] [Related]
19. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
20. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
